The incidence and mortality of esophageal cancer are high, with strong invasiveness and poor prognosis. In China, the number of morbidity and death accounts for about half of the world. The cause of the disease has not yet been clarified, and it is known to be related to many factors such as chronic damage to the upper digestive tract caused by poor diet and lifestyle, heredity and environment. With the continuous advancement of molecular biology technology, metagenomics and high-throughput sequencing began to be used as non-culture methods instead of traditional culture methods for micro-ecological analysis, and is becoming a research hotspot. Many studies have shown that the disturbance of upper digestive tract microecology may be one of the causes of esophageal cancer, which affects the occurrence and development of esophageal cancer through complex interactions with the body and various mechanisms. This paper reviews the research progress, which is of great significance to further clarify the value of upper gastrointestinal microecology in the pathogenesis, diagnosis and treatment of esophageal cancer.
Venous thromboembolism (VTE), comprising both deep vein thrombosis and pulmonary embolism, is a chronic illness that contributes significantly to the global burden of disease. The American College of Chest Physicians (ACCP) published the 9th edition of antithrombotic treatment guidelines for VTE (AT9) in 2012, which was first updated in 2016. In October 2021, ACCP published the 2nd update to AT9, which addressed 17 clinical questions related to VTE and presented 29 guidance statements in total. In this paper we interpreted the recommendations proposed in this update of the guidelines.
Objective To investigate the biological characteristics and clinical significance of cuproptosis-related genes in lung adenocarcinoma (LUAD) based on the multi-omics data from The Cancer Genome Atlas. Methods The cuproptosis-related genes were obtained from a study published in Science in March 2022. The whole genome data were used to reveal the mutation spectrum and copy number variation landscape of cuproptosis-related genes in LUAD and analyze its effects on transcriptome expression. Cuproptosis-related genes were annotated using Metascape analysis to further understand the pathways or functions in which these genes were involved. Subsequent univariate Cox analysis and Kaplan-Meier methods determined the prognosis of these genes in LUAD patients, and CellMiner analysis were used to identify those potential anticancer drugs for potentially targeting cuproptosis-related genes. Results Cuproptosis-related genes were less frequently mutated in LUAD, and the effect of gene mutations on transcriptomic expression may depend on the type of mutation. Gene copy number variation was an important factor resulting in the disordered expression of cuproptosis-related genes. The 16 cuproptosis-related genes were mainly involved in glyoxylate metabolism and glycine degradation, copper ion entry, proteolitidylation, cellular amino acid catabolism process, oxidative stress response, etc. Among them, 6 genes (DLD, FDX1, DLAT, DLST, PDHA1, CDKN2A) were prognostic risk genes in LUAD. The CellMiner analysis suggested that 13 drugs were associated with 7 cuproptosis-related genes and they might be potential anticancer drugs for potentially targeting cuproptosis. Conclusion This study reveals the biological characteristics and clinical significance of cuproptosis-related genes in LUAD, and provides some reference and theoretical basis for the subsequent research of cuproptosis in cancer.
The article titled "The global burden of lung cancer: Current status and future trends" which is recently published in Nature Reviews Cinical Oncology has provided a detailed analysis of the current global status of lung cancer. This article focuses on the global burden of lung cancer, risk factors, related prevention, control measures and treatment progress. Based on the current situation of lung cancer in the world, this paper analyzes the current situation of lung cancer in China, and briefly interprets the key points of prevention as well as control measures in the article.
With the release of outcomes from multiple phase 2 and phase 3 clinical trials, the multidisciplinary management protocols for early-stage resectable non-small cell lung cancer (rNSCLC) are experiencing expedited evolution. These studies have elucidated the pronounced efficacy of neoadjuvant and adjuvant therapies in enhancing the prognosis of rNSCLC patients, concurrently highlighting the imperative need for the revision and enhancement of congruent therapeutic regimens and clinical pathways. In light of this, the International Association for the Study of Lung Cancer (IASLC) has constituted a heterogeneous, multidisciplinary international consortium of experts to appraise ongoing clinical trials pertinent to rNSCLC, offering diagnostic, staging, and therapeutic recommendations for patients with stage Ⅱ and Ⅲ rNSCLC in accordance with the American Joint Committee on Cancer-Union for International Cancer Control, 8th Edition (AJCC-UICC 8th Edition). The document "Neoadjuvant and adjuvant therapy for early-stage resectable non-small cell lung cancer: Consensus recommendations from the International Association for the Study of Lung Cancer" enumerates a total of 20 recommendations, with 19 garnering consensus approval from over 85% of the experts. It is stipulated that patients with early-stage rNSCLC should undergo multidisciplinary team evaluations and complete requisite radiological assessments prior to definitive diagnosis. For patients with stage ⅢA or ⅢB, neoadjuvant chemotherapy and immunotherapy are advocated, whereas such therapies are not recommended for patients harboring epidermal growth factor receptor (EGFR) or anaplasticlymphoma kinase (ALK) mutations sensitive to tyrosine kinase inhibitors (TKIs). Postoperatively, adjuvant immunotherapy is considered contingent upon programmed cell death ligand 1 (PD-L1) expression levels, and additional oncogenic driver genes are scrutinized. For patients with specific genetic mutations, adjuvant therapy with osimertinib or alectinib is endorsed. These recommendations are designed to afford individualized, precision therapeutic strategies for patients with early-stage rNSCLC, thereby augmenting the efficacy of neoadjuvant and adjuvant therapies. This article delves into an in-depth elucidation of these consensus recommendations.
目的 探讨单孔胸腔镜下前纵隔支气管囊肿切除的治疗效果。 方法 回顾性分析 2009 年 3 月至 2015 年 4 月我院 26 例前纵隔支气管囊肿患者的临床资料，其中男 17 例、女 9 例，平均年龄 32.4（25～51）岁。均行单孔胸腔镜手术治疗，分析其临床症状、影像学特点及手术疗效。 结果 本组 26 例患者平均手术时间 62.0（48～110）min，平均出血量 98.4（60～120）ml，术后平均住院时间 8.7（6～12）d。术后 25 例患者无手术并发症，1 例术后因不配合主动咳嗽，出现肺不张及胸腔积液，给予调整胸腔引流管，加强咳嗽后恢复良好。术后平均随访 9.6（1～18）个月，复查 CT 均无复发。 结论 前纵隔支气管囊肿难以根据影像学诊断，最终需术后病理检查确诊。单孔胸腔镜手术可作为治疗前纵隔支气管囊肿首选方法。
Lung cancer is the malignancy with the highest incidence and mortality rate in China. In recent years, the popular use of low-dose computed tomography in the population has led to an increase in the detection rate of pulmonary nodules. The National Comprehensive Cancer Network (NCCN) updated and released the NCCN clinical practice guidelines in oncology for non-small cell lung cancer (version 2.2023) on February 17, 2023. This article will interpret the main updates of the new guideline and compare it with the domestic lung cancer treatment guidelines, providing new ideas for the diagnosis and treatment of lung cancer for Chinese clinicians.
Lung cancer is the malignant tumor with the highest incidence rate in men and the highest mortality rate in men and women in China, and the incidence and mortality rates are still increasing. Lung cancer screening is an important initiative for early detection of lung cancer and improvement of prognosis. The National Comprehensive Cancer Network (NCCN) updates the NCCN Clinical Practice Guidelines for Lung Cancer Screening annually, and the 2023 V2 edition was released in May 2023. The guidelines are based on the latest research advances and high-level evidence-based medical evidence to establish screening criteria for lung cancer, especially for non-small cell lung cancer, which is the most common and highly regarded type of lung cancer, and has received widespread attention from physicians worldwide. In this article, the latest version of the guideline will be interpreted based on China's national situation and Chinese lung cancer screening guidelines, with the aim of providing an updated reference for lung cancer screening in China.
The tyrosine kinase activity of epidermal growth factor receptor (EGFR) plays a key role in tumor cell proliferation, invasion, migration, and drug resistance. Studies have shown that non-small cell lung cancer patients with somatic driver gene EGFR mutations are sensitive to and can benefit from EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Nevertheless, EGFR-TKIs-related adverse events should not be ignored. Common adverse events such as diarrhea, acne-like rash and paronychia are usually manageable; although the incidence of interstitial lung disease is low, once it occurs, it is a serious threat to patients' life, and its pathogenesis is still unclear. There is very limited animal experimental and clinical research evidence on the potential mechanism of EGFR-TKIs-related interstitial lung disease in the available literature. Based on this, this article reviews the association between EGFR-TKIs and interstitial lung disease, at the same time, also discusses the research progress of EGFR-TKIs-related interstitial lung disease in combination with cytotoxic drugs or immunotherapeutic drugs and EGFR-TKIs, in order to provide a reference for the prevention and treatment of EGFR-TKIs-related interstitial lung disease in clinical practice in the future.